Astec LifeSciences Limited has announced its consolidated financial results for the fourth quarter and year ended 31st March 2026, showcasing significant growth in revenue and a reduction in losses.
In the fourth quarter of FY26, Astec LifeSciences reported a consolidated total income of ₹161.3 crore, marking a 34% increase compared to ₹120.3 crore in the same quarter of the previous fiscal year. The company’s consolidated EBITDA for Q4 FY26 stood at ₹11.8 crore, up from ₹6.3 crore in Q4 FY25, reflecting an 86.9% growth. Despite these improvements, the company reported a loss after tax of ₹7.7 crore in Q4 FY26, compared to a loss of ₹16.1 crore in Q4 FY25.
For the full fiscal year FY26, Astec LifeSciences achieved a consolidated total income of ₹453.2 crore, a 17.1% rise from ₹386.9 crore in FY25. The company reached an EBITDA breakeven with ₹0.5 crore in FY26, a significant turnaround from an EBITDA loss of ₹60.6 crore in FY25. However, the company reported a net loss of ₹80.9 crore in FY26, which is an improvement from the ₹134.7 crore loss in FY25.
The financial results were influenced by exceptional items related to regulatory changes in labour codes, which resulted in a financial impact of ₹2.1 crore, including gratuity and long-term compensated absences.
Chairperson Vishal Sharma commented on the performance, highlighting the strong revenue growth driven by improved volumes in both the Enterprise and Contract Manufacturing segments. This growth led to a significant margin expansion, with EBITDA growing to ₹11.8 crore in Q4 FY26 from ₹6.3 crore in Q4 FY25.
Astec LifeSciences continues to demonstrate a healthy sales mix of both exports and domestic sales, with exports reaching ₹103.7 crore in Q4 FY26, an 8% increase year-on-year, while domestic sales surged by 133.8% to ₹54.9 crore.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).